[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
Anna RoppeltM S LebedkinaAnton A ChernovTat'yana S KruglovaOlgo A MukhinaYu D YukhnovskayaF A SamedovaU A MаrkinaG V AndrenovaAlexander V KaraulovMar'yana A LysenkoDarya S FominaPublished in: Terapevticheskii arkhiv (2023)
The use of tixagevimab/cilgavimab in patients with PIDs is effective as pre-exposure prophylaxis and reduces the risk of severe COVID-19.